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Abstract
The lack of a suitable small animal model for the analysis of hepatitis C virus (HCV) infection has hampered elucidation of
the HCV life cycle and the development of both protective and therapeutic strategies against HCV infection. Human and
mouse harbor a comparable system for antiviral type I interferon (IFN) induction and amplification, which regulates viral
infection and replication. Using hepatocytes from knockout (ko) mice, we determined the critical step of the IFN-inducing/
amplification pathways regulating HCV replication in mouse. The results infer that interferon-beta promoter stimulator (IPS-
1) or interferon A receptor (IFNAR) were a crucial barrier to HCV replication in mouse hepatocytes. Although both IFNARko
and IPS-1ko hepatocytes showed a reduced induction of type I interferons in response to viral infection, only IPS-1-/- cells
circumvented cell death from HCV cytopathic effect and significantly improved J6JFH1 replication, suggesting IPS-1 to be a
key player regulating HCV replication in mouse hepatocytes. We then established mouse hepatocyte lines lacking IPS-1 or
IFNAR through immortalization with SV40T antigen. Expression of human (h)CD81 on these hepatocyte lines rendered both
lines HCVcc-permissive. We also found that the chimeric J6JFH1 construct, having the structure region from J6 isolate
enhanced HCV replication in mouse hepatocytes rather than the full length original JFH1 construct, a new finding that
suggests the possible role of the HCV structural region in HCV replication. This is the first report on the entry and replication
of HCV infectious particles in mouse hepatocytes. These mouse hepatocyte lines will facilitate establishing a mouse HCV
infection model with multifarious applications.
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Introduction
Chronic hepatitis C virus (HCV) infection is a major cause of
mortality and morbidity throughout the world infecting around
3.1% of the world’s population [1]. The development of much
needed specific antiviral therapies and an effective vaccine has
been hampered by the lack of a suitable small animal model. The
determinants restricting HCV tropism to human and chimpanzee
hosts are unknown. Replication of HCV strain JFH1 has been
demonstrated in mouse cells only upon antibody selection [2],
highlighting the very limited replication efficiency. Human CD81
and occludin have been implicated as important entry receptors
for retrovirus particles bearing HCV glycoproteins, HCV
pseudoparticles (HCVpp), into NIH3T3 murine cells [3].
However, HCV infection, spontaneous replication and particle
production by mouse cells have not yet been reported.
In mammalian cells, the host detects and responds to infection
by RNA-viruses, including HCV, by primarily recognizing viral
RNA through several distinct pathogen recognition receptors
(PRRs), including the cell surface and endosomal RNA sensors
Toll-like receptors 3 and 7 (TLR3 and TLR7), and the
cytoplasmic RNA sensors retinoic acid-inducible gene I (RIG-I)
and melanoma differentiation associated gene 5 (MDA5) [4]. The
detection of virus infection by these receptors leads to the
induction of interferons (IFNs) and their downstream IFN-
inducible anti-viral genes through distinct signaling pathways
[5]. Type I IFN is an important regulator of viral infections in the
innate immune system [6]. Another type of IFN, IFN-lambda,
affects the prognosis of HCV infection, and its response to antiviral
therapy [7,8].
Mutations impairing the function of the RIG-I gene and the
induction of IFN were essential in establishing HCV infectivity in
human HuH7.5 cells [9]. Similarly, the HCV-NS3/4a protease is
known to cleave IPS-1 adaptor molecule, inducing further
downstream blocking of the IFN-inducing signaling pathway
[10]. These data clearly demonstrate that the host RIG-I pathway
is crucial for suppressing HCV proliferation in human hepato-
cytes. Using a similar strategy, we investigated whether suppress-
ing the antiviral host innate immune system conferred any
advantage on HCV proliferation in mouse hepatocytes. We
examined the possibility of HCV replication in mice lacking the
expression of key factors that modulate the type I IFN-inducing
pathways. Only gene silencing of the IFN receptor (IFNAR) or
IPS-1 was sufficient to establish spontaneous HCV replication in
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replication, which is required for further in vitro studies of the HCV
life cycle in mouse hepatocytes, we immortalized IFNAR- and
IPS-1-knockout (ko) mice hepatocytes with SV40 T antigen. Upon
expression of the human (h)CD81 gene, these newly established
cell lines were able to support HCV infection for the first time in
mouse hepatocytes. Viral factors required for HCV replication in
mouse hepatocytes were also analyzed.
Results
IPS-1-mediated IFN signaling is important for HCV
replication in mouse hepatocytes
As a first step in establishing HCV infection in mice, we tested
the susceptibility of mouse hepatocytes to persistent expression of
HCV proteins after RNA transfection. In vitro transcribed chimeric
J6JFH1 RNA, in which the HCV structural and non-structural
regions were from J6 and JFH1 isolates respectively, was
transfected into hepatocytes from wild-type mice. We used a
highly sensitive polyclonal antibody derived from HCV-patient
serum for the detection of HCV proteins. No HCV proteins were
detected five days after transfection (Fig. 1 A), suggesting that wild-
type mouse hepatocytes were unable to maintain HCV replication.
We then tried to find and block the pathway used by mouse
hepatocytes for the detection of viral-RNA and the induction of
IFN response. Mouse hepatocytes did not show the expression of
either TLR3 or TLR7 as detected by RT-PCR, unlike IPS-1 and
RIG-I which was fairly detected (Fig. S1), suggesting that the
cytoplasmic RIG-I/IPS-1 pathway is the main pathway utilized by
mouse hepatocytes for the detection of RNA viruses. We then
checked the susceptibility of hepatocytes from TICAM-1ko, IPS-
1ko and IFNARko mice to the prolonged expression of HCV
proteins (Fig. 1B–D). Only IPS-1- and IFNARko mouse
hepatocytes showed expression of J6JFH1 proteins five days after
transfection (Fig. 1), indicating the importance of impaired IPS-1
and/or IFNAR receptors for HCV persistence. Similarly, the
detection of the J6JFH1-RNA in transfected hepatocyte lines from
various knockout mice showed higher levels in IPS-1 or IFNAR
knockout cells compared to TICAM-1knockout cells in which a
rapid decline of J6JFH1-RNA levels was noticed similar to the
non-replicating control JFH1GND construct (Fig. S2). These data
clearly suggest that the RIG-I/IPS-1 but not TLR3/TICAM-1 is
the main pathway utilized for the detection of HCV-RNA and the
induction of anti-viral immune response in mouse hepatocytes. Its
suppression significantly improves HCV replication in mouse
hepatocytes.
Establishment and characterization of immortalized
mouse hepatocyte cell lines lacking expression of the
IFNAR or IPS-1 gene
We further established mouse hepatocyte lines with disrupted
IFNAR or IPS-1 genes through immortalization with SV40T
antigen, and used these cell lines to study factors required for the
HCV life cycle. Hepatocytes were transduced with SV40T-
expressing lentivirus vectors. Six weeks after transduction,
hepatocytes transduced with SV40T showed continuous prolifer-
ation and clonally proliferating hepatocyte lines were selected.
SV40T-immortalized IFNARko and IPS-1ko clones were desig-
nated IRK (Fig. 2 A) and IPK (Fig. 2 B), respectively. 20 IRK and
19 IPK clones were picked up, of which IRK clones 2 and 4 (IRK2
and IRK4) and IPK clones 10 and 17 (IPK10 and IPK17) were
most closely related to primary mouse hepatocytes in term of
differentiation (Fig. 2 C) and were used in the following
experiments. Expression of SV40T was confirmed by RT-PCR
analysis (data not shown). IRK2, IRK4, IPK10 and IPK17, but
not the non-hepatocytic NIH3T3 cells, displayed albumin and
hepatocyte nuclear factor 4 (HNF4) expression similar to that
observed in liver tissue, but did not express the bile duct marker,
cytokeratin. IRK and IPK cells did not show expression of IFNAR
and IPS-1 respectively (Fig. 2 C).
Replication of the HCV genome in IRK and IPK cells
To assess the permissiveness of the established cell lines to HCV
replication, we transduced IRK4 and IPK17 cells with J6JFH1
RNA and monitored the HCV protein and RNA levels by IF
(Fig. 3 A) and real time RT-PCR (Fig. 3 B). The number of cells
expressing HCV proteins, as detected by IF, increased over time,
indicating the continuous proliferation of J6JFH1 in these cells.
However, the ratio between infected and non-infected cells did not
significantly change over time for 7 days after transfection.
Similarly, the amount of total J6JFH1 RNA in 1 mg of total
cellular RNA was reasonably constant. By contrast, the level of
Figure 1. IF detection of of J6JFH1 proteins’ expression 5 days after transfection of J6JFH1-RNA through electroporation into wild
type (A), TICAM-1ko (B), IPS-1ko (C), and IFNARko (D), freshly isolated primary hepatocytes. A highly sensitive polyclonal antibody
extracted from HCV-patient serum (AbS3) was used for the detection. Staining of the uninfected hepatocytes from different Ko mice was also
performed and they showed negative for HCV proteins (data not shown).
doi:10.1371/journal.pone.0021284.g001
Mouse Hepatocytes for HCV
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replication, rapidly declined, indicating the requirement of
continuous HCV replication for the maintenance of HCV
positivity in the transfected mouse hepatocytes. Similar data were
obtained from IRK2 and IPK10 cells (data not shown).
IPS-1-dependent/Interferon-independent pathway is
responsible for HCV’s cytopathic effect
In comparison to IPS-1ko hepatocytes, J6JFH1-RNA in
IFNARko were lower and decreased further after its transfection,
while higher stable levels of J6JFH1-RNA were maintained in IPS-
1ko cells (Fig. 3 B and Fig. S2). Similarly, larger numbers of HCV-
positive cells were detected in IPS-1ko hepatocytes compared with
their IFNARko counterparts (Fig. 3 A), suggesting that the IPS-1
disruption benefits HCV replication in a distinct manner from
IFNAR disruption. To measure the interferon induction after
RNA virus infection in those cells, we used a highly infectious
RNA-Virus (VSV) and measured the induction of interferon after
its infection. All the interferons measured showed similar
suppression of induction in IFNARko and IPS-1ko hepatocytes
(Fig. 4). Surprisingly, cellular cytopathic effect that was monitored
after transfection of J6JFH1-RNA was markedly reduced in IPS-
1ko but not in IFNARko hepatocytes after transfection (Fig. 5A).
This suppression was accompanied by an increase of J6JFH1-
RNA levels in IPS-1ko cells, suggesting that minimal cellular
damage induced by HCV replication in IPS-1-/- cells led to the
improvement of HCV proliferation in mouse hepatocytes
(Fig. 5B).Reduction of HCV-induced cellular cytotoxicity (Fig.5C),
and improvement of HCV replication (Fig.5D) in wild type, and
IFNAR-KO cells were found when we cultured the cells with a
pan-caspase inhibitor, zVAD-fmk, 2 days before and after HCV-
RNA transfection. We reasoned that the IPS-1 pathway rather
than the IFNAR pathway capacitates hepatocytes to induce HCV-
derived apoptotic cell death and its disruption resulted in the
circumvention of cell death.
Human CD81 is required for HCV infection of mouse
hepatocytes
Similar to the primary mouse hepatocytes, immortalized mouse
hepatocytes showed the expression of all the mouse counterparts of
human HCV entry receptors (Fig. S3). Human CD81 and
hOccludin, but not other human HCV receptors such as SR-B1
or claudin1, have previously been reported to be essential for
HCVpp entry into NIH3T3 mouse cells [3]. We then expressed
hCD81 and/or hOccludin in IRK2 and IRK4 cells using
lentivirus vectors. Using a MOI of 10, 95% transfection efficiency
was achieved (Fig. S4) with lentivirus vector. We next tested the
effect of these proteins on HCV particle (HCVcc) infection.
Human CD81 alone was found to be required for J6JFH1
infection into all IRK and IPK cells tested (Fig. S5 and Fig. 6 A,
and B). For the first time in mouse hepatocytes, HCV proteins
were detected in nearly 1% of the cells used for infection. These
data demonstrated the importance of hCD81 in establishing
HCVcc infection in mouse hepatocytes.
Viral factors affecting HCV replication in mouse
hepatocytes
After successfully establishing J6JFH1 infection in mouse
hepatocytes, we attempted to infect these cells with other strains
of HCV. Human CD81-expressing IPK17 cells were infected with
full-length JFH1FL, however, no infection was detected (data not
shown). This might be due to a problem in infection and/or
replication. We further examined the replication efficiency of
JFH1FL, the subgenomic JFH1 replicon and the J6JFH1 chimera
in two different mouse hepatocyte lines and the HuH7.5.1 cell line.
The persistent expression of HCV proteins was detected seven
days after RNA transfection. Although HCV proteins were
detected in HuH7.5.1 cells in all cases (Fig. 7 C), only J6JFH1
proteins were detected in the mouse hepatocyte lines, suggesting
for the first time the importance of the J6 structural region for the
replication of HCV in mouse hepatocytes (Fig. 7 A, and B).
Figure 2. Morphological characteristics of IRK-4 (A) and IPK-17 (B) cells. (C) RT analysis for the expression of albumin, HNF4, cytokeratin,
interferon A receptor, and IPS-1 in 2 IFNAR-KO cell lines (IRK2 and 4), 2 IPS-1-KO cell lines (IPK-10 and 17), total liver, and NIH3T3 cells.
doi:10.1371/journal.pone.0021284.g002
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Gene silencing of either IPS-1 or IFNAR significantly improves
HCV replication and persistence in mouse hepatocytes compared
with wild-type or TICAM-1ko mice. This result demonstrated the
importance of the IPS-1 pathway rather than the TICAM-1
pathway in the induction of type I IFN by HCV infection, and
revealed that the IFNAR amplification pathway confers resistance
to HCV in mouse hepatocytes independently of TICAM-1. In
accordance with our data, HCV-NS3/4A protease is known to
cleave the IPS-1 and/or RIG-I-complement molecules including
DDX3 and Riplet in humans to overcome the host innate immune
response, showing the importance of RIG-I/IPS-1 pathway
suppression in the establishment of HCV infection [10,11,12].
To further study factors affecting the HCV life cycle in mouse
hepatocytes, we established IPK and IRK immortalized mouse
hepatocyte lines by transduction with SV40T antigen. The
established hepatocytes cell lines showed expression of HNF4, a
major hepatocyte transcription factor, required for hepatocyte
differentiation and liver-specific gene expression [13]. The
maintenance of hepatocellular functions was demonstrated by
continuous expression of hepatocyte specific differentiation
marker, albumin, and the lack of expression of the bile duct
marker, cytokeratin. The close resemblance of these cell lines to
primary mouse hepatocytes is crucial to ensure the physiological
relevance of factors identified in these cell lines that affect the
HCV life cycle.
It is worth noting that HCV replication in IPS-1ko was higher
than that in IFNARko hepatocytes. Since IPS-1 is present
upstream of IFNAR in the IFN-amplification pathway, this higher
J6JFH1 replication efficiency in IPS-1ko hepatocytes suggested the
presence of an additive factor affecting HCV replication other
than the induction of IFNAR-mediated type I IFN. This enhanced
replication efficiency was also not accompanied by the induction
of other interferon types, but was correlated with the reduction of
HCV-induced apoptosis in mouse hepatocytes. This data clearly
demonstrates that IPS-1 is playing an important role in the
regulation of HCV infection in mouse hepatocytes through two
different pathways, the IFN-induction pathways and another new
IFN-independent pathway, leading to apoptotic cell death and
elimination of HCV-harboring hepatocytes. The cytopathic effect
of HCV infection in human cells is still contradictory. Although,
some reports showed the induction of apoptosis and cell death by
HCV infection in human hepatocytes [14,15,16], others showed
suppression of apoptosis by HCV proteins [17,18]. This difference
may be due to the different cell lines used in the different studies.
Almost all the studies reporting HCV-induced apoptosis used
Figure 3. Proliferation of HCV in IRK4 and IPK17 cells over time as detected by immunofluorescence staining of NS5a protein using
the CL1 rabbit polyclonal antibody (A) and by quantitative real-time RT-PCR analysis of HCV-RNA levels (B). JFH1GND was used as a
negative control to exclude non replicating HCV-RNA. The data plotted represent the average +/2 STD of 3 different experiments.
doi:10.1371/journal.pone.0021284.g003
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that the inability to undergo apoptosis is essential for the
development of cancer [19,20,21], our use of immortalized, non-
cancerous hepatocytes may make it possible to reproduce the
physiological response of the cells to HCV infection more closely.
The IPS-1 regulation of cell death following the introduction of
HCV-RNA may also regulate the effector cell function. It is likely
that hepatocyte debris generated secondary to intrinsic production
of viral dsRNA in HCV-infected hepatocytes affect the antiviral
effector response of the immune system through maturation of
dendritic cells [22]. Hence, the effector cell activation may be
enhanced by the induction of cell death through the IPS-1
pathway in hepatocytes which may facilitate producing dsRNA-
containing debris.
In comparison to the JFH1GND construct with deficient
replication that showed a rapid reduction in its RNA levels over
time after transfection into mouse hepatocytes, J6JFH1 RNA was
detected at four-log higher levels and was maintained at a
relatively stable levels in IPS-1ko hepatocytes. Although the
number of mouse cells expressing HCV proteins was found to
increase over time, as detected by IF, the ratio between HCV-
negative and -positive cells did not show any significant change for
7 days after transfection and increased after 10 days (data not
shown). This indicates a negative selection of HCV-bearing cells
over time which may be due to slower cellular replication, or loss
of HCV replication. Another possibility may be that HCV
infection is affected by the presence of an inhibitory factor possibly
triggered by HCV replication or the lack of a human host factor
required for HCV replication. Due to the initial replication of
HCV in the transfected IPK and IRK mouse hepatocytes for the
first 7 days and the establishment of infection, we favor the
presence of a possible inhibitory factor that may be triggered by
HCV replication. Another factor that also limits HCV spread in
mouse hepatocytes is the failure of HCV to produce infectious
particles in these cells (data no shown).
Using this newly established immortalized mouse hepatocyte
line, we found that although J6JFH1, JFH1FL and the subgenomic
JFH1 replicon all share a similar non-structural region derived
from isolate JFH1 that is required for HCV replication, and
although all of these constructs can replicate efficiently in
HuH7.5.1 cells, strikingly, only J6JFH1 carrying the J6 structural
region replicated in mouse hepatocytes. This indicates the
importance of the J6 structural region and/or the chimeric
construct between J6 and JFH1 for HCV replication in mouse
hepatocytes. Structural regions are known to be important for
HCV entry and/or particle formation [23], but this is the first time
that their importance in replication in HCV-bearing cells has been
demonstrated. This finding clearly shows the importance of non-
hepatoma cell lines with less genetic abnormalities and mutations
for the discovery of new aspects of the life cycle of HCV.
Although, the co-expression of human CD81 and Occludin
genes was found to be important for HCVpp entry into murine
NIH3T3 cells [3], the expression of hCD81 alone was sufficient for
J6JFH1 entry into mouse hepatocytes. This may be explained by
the different cell lines used in the different studies. In contrast to
NIH3T3 cells, we used immortalized hepatocytes that showed
close physiological resemblance to primary mouse hepatocytes and
showed the expression of all the mouse counterparts of HCV entry
Figure 4. Wild type, IFNARko, and IPS-1ko mice hepatocytes were infected with mock or VSV virus, 2 and 6 hours later, total RNA
was extracted from the cells, and interferon alpha, beta, gamma and lambda mRNA induction levels were measured by real-time
RT-PCR. Similar results were obtained from 2 different experiments, each was performed in duplicates. The data plotted represent the mean
duplicate readings in one of them.
doi:10.1371/journal.pone.0021284.g004
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mutations in HCV envelope proteins allowing its interaction with
murine CD81 is enough for efficient HCVpp entry without the
expression of any human entry receptors in murine cells [24]. This
report, together with ours, suggest that CD81 is the main human
host restriction factor for HCV entry, and that overcoming this
problem either by HCV adaptation to murine CD81, or the
expression of human CD81 in murine hepatocytes is essential for
HCV entry. Although our lentivirus transfection efficiency with
CD81 wasaround 95%in IPKand IRK clones,only1% of the cells
were prone to infection with HCVcc. Also, HCVpp showed lower
entry levels in those cells compared to HuH7.5.1 cells (Fig. S6). This
suggests that hCD81 expression is the minimum and most crucial
requirement for HCV entry into mouse hepatocytes. The discovery
and expression of other co-receptors facilitating HCV entry in
human cells is still required for efficient and robust HCV infection.
In summary, the suppression of IPS-1 is important for the
establishment of HCV infection and replication in mouse
hepatocytes through the suppression of both interferon induction
and interferon independent J6JFH1-induced cytopathic effect. We
have established hepatocytes lines from IPS-1 and IFNARko mice
that support HCV replication and infection. These cell lines will
be very useful in identifying other species restriction factors and
viral determinants required for further establishment of a robust
and efficient HCV life cycle in mouse hepatocytes. Using those
cells, we showed for the first time the importance of HCV
structural region for viral replication. IRF3ko mouse embryo
fibroblasts (MEFs) were previously shown to support HCV
replication more efficiently than wild MEFs [25]. Since the
knockout of IPS-1 mainly suppresses signaling in response to virus
RNA detection, and maintains an intact IFN response to other
stimulants, it may result in minimum interference to adaptive
immune responses as compared to IRF3 or IFNARko. Therefore,
further development of hCD81-transgenic IPS-1ko mice may
serve as a good model for the study of immunological responses
against HCV infection. This mouse model can be used as a
backbone for any further future models supporting robust HCV
infectivity for the study of HCV pathogenesis, propagation and
vaccine development.
Material and Methods
Cell culture
HuH7.5.1cellswereculturedinhigh-glucoseDulbecco’smodified
Eagle’s medium (DMEM; Gibco/Invitrogen, Tokyo, Japan) supple-
mented with 2 mM L-glutamine, 100 U of penicillin/ml, 100 mgo f
Figure 5. Measurement of J6JFH1 mediated cytopathic effect in wild type, IFNARko, and IPS-1ko mouse hepatocytes. Cultrure
medium were left untreated (A;B) or treated with 20 mM of zVAD-fmK (C;D) 2 days before and after J6JFH1-RNA transfection. One day after
transfection of J6JFH1-RNA, culture medium was discarded and cells were washed with PBS. A new medium was added and cells were cultured for
another 24 hours. The LDH activity in the culture medium was measured in 2 different experiments in duplicates and showed similar results, the
average levels of a duplicate from a single experiment was plotted (A, C). HCV-RNA titers in the cells were also measured using real-time RT-PCR (B,
D), the data shown represent the mean +/2 STD of 3 different experiments.
doi:10.1371/journal.pone.0021284.g005
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hepatocytes were isolated from the liver using collagenase
perfusion through the inferior vena cava (IVC), while clamping
the animal’s intrathoracic extension. Hepatocyte isolation and
perfusion control were performed as previously described [26].
Primary and immortalized hepatocytes were cultured in a similar
medium supplemented with: HEPES (Gibco/Invitrogen),
20 mmol/L; L-proline, 30 mg/mL; insulin (Sigma, St. Louis,
MO, USA), 0.5 mg/mL; dexamethasone (Wako, Osaka, Japan),
1610
27 mol/L; NaHCO3, 44 mmol/L; nicotinamide (Wako),
10 mmol/L; EGF (Wako), 10 ng/mL; L-ascorbic acid 2-phos-
phate (Wako), 0.2 mmol/L; and MEM-non essential amino acids
(Gibco/Invitrogen), 1%.
Gene-disrupted mice
All mice were backcrossed with C57BL/6 mice more than seven
times before use. Toll-like receptor adaptor molecule 1 (TICAM-
1) ko [27] and IPS-1ko mice [28] were generated in our laboratory
(detailed information regarding the IPS-1 mice will be presented
elsewhere). All mice were maintained under specific-pathogen-free
conditions in the animal facility of the Hokkaido University
Graduate School of Medicine (Japan).
RNA extraction, reverse transcriptase polymerase chain
reaction (RT-PCR) and real-time RT-PCR
RNA was extracted from cultured cells using Trizol reagent
(Invitrogen, San Diego, CA, USA) according to the manufactur-
er’s protocol. Using 1 mg of total RNA as a template, we
performed RT-PCR and real-time RT-PCR as previously
described [29,30].
In vitro RNA transcription, transfection and preparation of
J6JFH1 and Jfh1 viruses
In vitro RNA transcription, transfection into HuH7.5.1 or mouse
hepatocytes, and preparation of J6JFH1 and JFH1 viruses, were all
performed as previously reported [31]. RNA transfection into
human and mouse hepatocytes was performed by electroporation
using a Gene Pulser II (Bio-Rad, Berkeley, California) at 260 V
and 950 Cap.
HCV infection
J6JFH1 and JFH1 concentrated medium were adjusted to
contain a similar RNA copy number by real-time RT-PCR.
2610
4 cells/well were cultured in 8-well glass chamber slides.
After 24 hours, the medium was removed and replaced by
concentrated medium containing JFH1 or J6JFH1 viruses. After
three hours, the concentrated medium was removed, cells were
washed with PBS and incubated in fresh medium for 48 hours,
before the detection of infection.
Lentivirus construction, titration and infection
The gene encoding T antigen from simian virus was cloned
from plasmid CSII-EF-SVT [32]. The genes encoding human
CD81 and occludin were cloned from HuH-7.5.1 cells using the
Zero Blunt TOPO PCR Cloning Kit (Invitrogen) according to the
manufacturer’s protocol. These genes were then inserted into the
GFP reporter gene-containing lentiviral expression (pLBIG) vector
using the EcoRI and XhoI restriction sites for SV40T and hCD81,
and the XbaI and XhoI restriction sites for hOccludin. Lentivirus
expression vectors were then constructed as previously described
[27]. GFP expression was used for the titration of lentivirus
vectors, and a multiplicity of infection (MOI) of 10 was used for
the infection of mouse cells. Forty-eight hours after the transfection
of hCD81 and/or hOccludin, cells were trypsinized and counted.
Then, 2610
4 cells/well were cultured in 8-well glass chamber
slides for HCV infection and 5610
4 cells/well were cultured in
12-well plates, along with 1 ml of medium containing HCVpp, for
HCV entry experiments.
HCVpp construction and the detection of luciferase
expression
HCVpp containing the E1 and E2 proteins from HCV isolate
J6 and expressing the luciferase reporter gene were a kind gift from
Dr. Thomas Pietschmann at the TWINCORE Center for
Experimental and Clinical Infection Research, Germany. The
production of HCVpp and the measurement of luciferase levels
were performed as previously described [33].
Indirect immunofluorescence (IF)
IF expression of HCV proteins was detected in the infected cells
using antibodies in the serum of chronic HCV patients or rabbit
IgG anti-NS5A antibody (Cl-1) (both kind gifts from K.
Shimotohno, Chiba Institute of Technology, Japan). Goat anti-
human IgG Alexa 594 and goat anti-rabbit Alexa 594 (Invitrogen)
were used as secondary antibodies, respectively. Fluorescence
Figure 6. J6JFH1 infection into IRK-4 and IPK17 cells. HCV-
NS5A protein detection in mouse IRK4 (A,B) and IPK17 (C,D)
and human 7.5.1 cells (E,F). The cells were transduced with
lentivirus expressing human CD81 gene at 10 MOI. 48 hours later the
cells were infected with 100 times concentrated supernatant medium,
collected during 1 week after transfection of HuH7.5.1 cells with
J6JFH1-RNA (A, C, and E) or JFH1GND-RNA (B, D, and F).
doi:10.1371/journal.pone.0021284.g006
Mouse Hepatocytes for HCV
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microscope (Zeiss, Jena, Germany).
Detection of cell death
Culture medium was collected from HCV infected and control
cells and used for measuring lactate dehydrogenase (LDH) levels
using an LDH cytotoxicity detection kit (Takara Biomedicals,
Tokyo, Japan). Light absorbance was then measured according to
the manufacturer’s protocol.
Ethic Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Committee on the Ethics of Animal
Experiments in the Animal Safety Center, Hokkaido University,
Japan. All mice were used according to the guidelines of the
institutional animal care and use committee of Hokkaido
University, who approved this study as ID number: 08-0243, ‘‘
Analysis of immune modulation by toll-like receptors’’.
Supporting Information
Figure S1 RT detection of TLR3, TLR7, RIG-I, and IPS-1
expression in mouse hepatocytes. GAPDH expression was used as
internal control, and RNA from CD11c+ spleenocytes (dendritic
cells) was used as positive control.
(TIF)
Figure S2 Proliferation of HCV in IPS-1, TICAM-1(TRIF) and
IFNAR-knockout mouse hepatocytes over time as detected by
quantitative real-time RT-PCR analysis of HCV-RNA levels.
JFH1GND transfection into IPS-1 knockout cells was used as a
negative control to exclude non replicating HCV RNA. The data
plotted represent the average +/2 STD of 3 different experi-
ments.
(TIF)
Figure S3 RT detection of CD81, Occludin, Claudin 1, SRB1,
and LDL receptor expression in primary, IRK4 and IPK17 mouse
hepatocytes. GAPDH expression was used as internal control.
(TIF)
Figure S4 Estimation of the transfection efficiency of lentivirus
vector expressing green fluorescent protein (GFP) as a reporter,
together with hCD81 or hOccludin. 48 hours after transfection
with the lentivirus vector, cells were trypsinized and GFP positive
cells were detected by BD FACSCalibur (BD Biosciences).
(TIF)
Figure S5 HCV infection of IRK2 cells transfected with
lentivirus expressing hCD81 and/or hOccludin. IRK2 cells were
transfected with lentivirus expressing empty vector (A), hCD81 (B),
hOccludin (C) or hCD81 and hOccludin (D) at a MOI of 10. After
48 hours, the cells were infected with concentrated J6JFH1
transfected 7.5.1 culture medium. After a further three hours, cells
were washed with PBS and incubated in fresh medium. After
another 48 hours, HCV infection was examined through the
detection of HCV-NS5a protein expression by immunofluores-
cence staining.
(TIF)
Figure S6 HCVpp entry into mouse cells. A similar number of
IPK17 and HuH7.5.1 were cultured in triplicate. IPK17 cells were
only transfected with lentivirus expressing hCD81, while
HuH7.5.1 cells were transfected with empty vector at a MOI of
Figure 7. Detection of HCV-NS5A protein in IRK-2 (A), IRK-4 (B) and HuH-7.5 cells (C) by IF 5 days after transfection with J6JFH1, FL-
JFH1 or subgenomic JFH1-RNA.
doi:10.1371/journal.pone.0021284.g007
Mouse Hepatocytes for HCV
PLoS ONE | www.plosone.org 8 June 2011 | Volume 6 | Issue 6 | e2128410. After 48 hours, the medium was replaced with a new medium
containing mock VSVG-pp or HCVpp expressing luciferase. After
another 48 hours, pseudoparticles entry was determined by
measuring the luciferase activity. In order to compare the HCVpp
entry between IPK17 and HuH7.5.1 cells, the luciferase
expression from VSV-Gpp entry was used an internal control,
while that from HCVpp was plotted relatively.
(TIF)
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